4932417I16Rik Inhibitors
Chemical inhibitors of protein 4932417I16Rik can interact with and modulate its activity through various intracellular signaling pathways. Staurosporine, as a broad-spectrum protein kinase inhibitor, can inhibit the kinase responsible for the phosphorylation and subsequent activation of 4932417I16Rik, leading to a decrease in its activity. Bisindolylmaleimide I, with its specificity towards protein kinase C (PKC), can also suppress the function of 4932417I16Rik if PKC phosphorylates and thereby regulates this protein. LY294002, targeting PI3K, can decrease the activity of 4932417I16Rik by blocking the PI3K/Akt pathway that may be upstream of the protein's activation. Similarly, U0126, which inhibits MEK1/2 in the MAPK pathway, can prevent the downstream activation of ERK and, consequently, the activation of 4932417I16Rik.
Further inhibitory effects can come from SB203580, which selectively targets p38 MAP kinase. If 4932417I16Rik is a downstream effector in the p38 MAPK signaling pathway, then SB203580 can suppress its activity. Rapamycin, targeting mTOR, can inhibit the activity of 4932417I16Rik if it is involved in mTOR-regulated processes. SP600125, as a JNK inhibitor, can reduce the activity of 4932417I16Rik by preventing JNK-mediated activation. PP2, an inhibitor of Src family kinases, can suppress the activation of 4932417I16Rik if Src kinases are involved in its activation. Additionally, inhibitors like gefitinib and erlotinib, which selectively inhibit EGFR tyrosine kinase, as well as lapatinib, which inhibits both HER2 and EGFR, can reduce the function of 4932417I16Rik if it operates downstream of these receptors. Lastly, sorafenib, as a multi-kinase inhibitor targeting RAF kinases, among others, can lead to the inhibition of 4932417I16Rik if it is regulated by RAF kinase activity within the MAPK signaling pathway.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Given that 4932417I16Rik is a protein that could be regulated by phosphorylation, staurosporine could inhibit the kinase that activates 4932417I16Rik, leading to its inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I specifically inhibits protein kinase C (PKC). If 4932417I16Rik is a substrate or is regulated by PKC, this inhibitor would prevent PKC from phosphorylating 4932417I16Rik, thus inhibiting its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K. Since PI3K is part of signaling pathways that may control the activity of various proteins, blocking PI3K can lead to a decrease in the activity of 4932417I16Rik if it is downstream of PI3K signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, which are upstream of ERK in the MAPK pathway. If 4932417I16Rik is activated by the MAPK pathway, inhibition of MEK would prevent the activation of ERK and subsequent activation of 4932417I16Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase. If the function of 4932417I16Rik relies on p38 MAPK signaling, inhibition by SB203580 would lead to decreased activity of 4932417I16Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a central regulator of cell growth and proliferation. If 4932417I16Rik is a protein involved in these mTOR regulated processes, its activity would be inhibited by rapamycin. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. If the JNK pathway is responsible for activating 4932417I16Rik, then inhibition by SP600125 would lead to a decrease in its activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor. If Src kinases are involved in the activation of 4932417I16Rik, PP2 would inhibit its activity by preventing Src kinase-mediated activation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits EGFR tyrosine kinase. If 4932417I16Rik is activated as part of the EGFR signaling cascade, then inhibition by gefitinib would reduce the activity of 4932417I16Rik. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an inhibitor of EGFR tyrosine kinase. Similar to gefitinib, if 4932417I16Rik functions downstream of EGFR, erlotinib would inhibit its activation and thereby inhibit the function of 4932417I16Rik. | ||||||